Navigation Links
New gene test offers personalized treatment for inherited neuromuscular disorder
Date:2/11/2011

The gene, GFPT1, has been identified by researchers at Newcastle University working with international colleagues, as crucial in causing a variation of Congenital Myasthenic Syndrome (CMS).

The condition came to prominence in recent times in the UK with the plight of baby RB, who was at the centre of a "right-to-life" legal dispute.

CMS is a rare genetic condition affecting the way signals travel between the brain and muscles which can cause paralysis and in some cases death. It affects one in every 500,000 births and the severity of the condition varies, depending on where the fault lies in the complex signals between the nerves and the muscles.

The variation of CMS identified by researchers, GFPT1, tends to develop in the first ten years of life with patients losing muscle strength and control in their hips and shoulders or arms and legs.

"The identification of this gene means that doctors can order genetic analysis and confirm the condition allowing earlier treatment with cholinesterase inhibitors," explained Professor Hanns Lochmller of the Institute of Human Genetics at Newcastle University.

"This offers an effective therapy which can be taken through life," he added.

The research also highlighted a new area to explore for future treatments as GFPT1 is involved in initiating the metabolism of amino sugar.

The international team, headed up by Dr. Jan Senderek from the University of Aachen in Germany and by Dr Juliane Mller from Newcastle University, analysed the genes of 13 families affected by the condition.


'/>"/>

Contact: Hanns Lochmuller
hanns.lochmuller@ncl.ac.uk
01-912-418-602
Newcastle University
Source:Eurekalert

Page: 1

Related biology news :

1. Worm genome offers clues to evolution of parasitism
2. Advance offers revolution in food safety testing
3. Light pollution offers new global measure of coral reef health
4. Rong Li Lab offers insight into adaptive ability of cells
5. International public-private partnership offers new paradigm for medicinal chemistry
6. UC Davis discovery offers hope for treating kidney cancer
7. New paper offers key insights into how new species emerge
8. Study offers clues to beating hearing loss
9. Fighting global warming offers growth and development opportunities
10. Brown-led team offers first look at how bats land
11. Star Trek-like technology offers noninvasive monitor for patients and athletes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
(Date:3/10/2016)... BELL, Pa. , March 10, 2016   Unisys ... U.S. Customs and Border Protection (CBP) is testing its ... San Diego to help identify certain ... States . The test, designed to help determine the ... pedestrian environment, began in February and will run until May ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... ... 2016 , ... NDA Partners Chairman Carl Peck, MD ... Consultant. Mr. Clark was formerly a Vice President with US Pharmacopeia, where ... monographs based on analytical methods. NDA Partners Expert Consultants are top tier ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO Benito ... the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received ... cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) ...
(Date:4/27/2016)... , April 27, 2016 ... research report with specific focus on US, EU, ... Japan , to the healthcare business intelligence ... library. Complete report on the Flow ... companies and supported with 282 tables and figures ...
Breaking Biology Technology: